Gupta, V. K., Giri, R., & Agrawal, S. (2021). Dipeptidyl peptidase-4 inhibitor (teneligliptin) significantly reduces liver fat content and delays progression of non-alcoholic steatohepatitis in type 2 diabetes mellitus patients. International Journal of Advances in Medicine, 8(12), 1817–1820. https://doi.org/10.18203/2349-3933.ijam20214516